Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma-Reference-Cited by-全球学者库

Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma

Published:2017-09 Issue:37 Volume:96 Page:e7655
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Lee Teng-Yu,Lin Chen-Chun,Chen Chiung-Yu,Wang Tsang-En,Lo Gin-Ho,Chang Chi-Sen,Chao Yee

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference33 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Earlier presentation and application of curative treatments in hepatocellular carcinoma;Ulahannan;Hepatology,2014

3. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005;Altekruse;J Clin Oncol,2009

4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.;Erratum in: J Hepatol,2012

5. Treatment of intermediate-stage hepatocellular carcinoma;Forner;Nat Rev Clin Oncol,2014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and complications of transarterial chemoembolization alone or in combination with different protocols for hepatocellular carcinoma: A Bayesian network meta-analysis of randomized controlled trials;iLIVER;2023-06

2. The reproducibility of interventional radiology randomized controlled trials and external validation of a classification system;Diagnostic and Interventional Radiology;2023-05-01

3. Premature Death in Bodybuilders: What Do We Know?;Sports Medicine;2023-01-30

4. Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma;Journal of Personalized Medicine;2022-03-23

5. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma;Frontiers in Oncology;2022-01-13